^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CYAD-101

    i
    Company:
    Celyad Oncology
    Drug class:
    NKG2DL-targeted CAR-T immunotherapy
    Related drugs:
    Apply
    Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer (KEYNOTE-B79) (NCT04991948)
    Phase 1
    Celyad Oncology SA
    Recruiting
    Last update posted :
    03/09/2022
    Initiation :
    11/22/2021
    Primary completion :
    08/21/2023
    Completion :
    05/25/2038
    MSI
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • CYAD-101